Mineralys Therapeutics Q1 2024 GAAP EPS $(0.70) Misses $(0.67) Estimate
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics (MLYS) reported a Q1 2024 GAAP EPS loss of $(0.70), missing the $(0.67) estimate by 4.48%, marking a 37.25% increase in losses from the same period last year.
May 09, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mineralys Therapeutics reported a larger than expected loss for Q1 2024, missing analyst estimates.
Missing earnings estimates, especially with an increased loss compared to the previous year, typically leads to negative investor sentiment and can result in a short-term decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100